Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

04/11/2015 - 3 minutes

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year.

This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers:

speakers_deal_2015_bio-europe

The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to be especially active in the first half of the year. As Golumbeski pointed out: it made a major immuno-oncology (PD-L1) deal with AstraZeneca, signed a $1 billion dollars upfront deal with CAR-T company Juno Therapeutics and bought Receptos for $7.2Bn.

A good starting point for the discussion, which started around the many IPOs which occurred since 2014. The moderator asked:

How does that impact your ‘deal activity’?

Golumbeski answered first: this provides an additional options for smaller Biotechs in addition to partnering. Also, the high valuation of Biotechs protects them from bigger Biotechs/Pharma willing to acquire the assets.

Related Content

Gaal from Almirall was on the same line.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: